Sarah Cannon, the global cancer institute of Hospital Corporation of America (HCA), offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom.
By bringing together a network of renowned cancer experts, we are collaborating and sharing best practices that address every aspect of the cancer journey, from screening and diagnosis through treatment and survivorship. Our research arm, Sarah Cannon Research Institute (SCRI), was formed more than 20 years ago to ensure patients could access cutting-edge therapies closer to home. In partnering with leading pharmaceutical/biotech companies and investigators, we offer more than 500 clinical trials annually.
In 2015 alone, Sarah Cannon participated in the development of 24 new drugs approved by the Food and Drug Administration (FDA) for cancer treatment. These new therapies are helping to advance the standard of care for patients, including immunotherapies, which help the body’s immune system detect and fight cancer. Collectively, our comprehensive patient-centric services ensure that we are fulfilling our mission to advance science and transform care.